Optimer climbs on US Dificid OK, but all eyes on launch success
This article was originally published in Scrip
Executive Summary
After winning US approval of its oral antibiotic Dificid (fidaxomicin) as a treatment for adults with Clostridium difficile-associated diarrhea (CDAD), a serious infection that can sometimes result in death, all eyes are on Optimer Pharmaceuticals’ launch of the drug.